Silo Pharma, Inc. (SILO)
NASDAQ: SILO · IEX Real-Time Price · USD
1.850
+0.010 (0.54%)
May 2, 2024, 4:00 PM EDT - Market closed
Silo Pharma Revenue
In the year 2023, Silo Pharma had annual revenue of $72.10K. Revenue in the quarter ending December 31, 2023 was $18.03K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
72.96
Revenue / Employee
$24,034
Employees
3
Market Cap
5.26M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72.10K | - | - |
Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
Dec 31, 2021 | 71.26K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 40.57K | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 49.84K | 2.70K | 5.72% |
Dec 31, 2015 | 47.14K | 26.58K | 129.23% |
Dec 31, 2014 | 20.57K | 19.94K | 3,190.40% |
Dec 31, 2013 | 625.00 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BIOLASE | 49.16M |
Regional Health Properties | 17.16M |
ThermoGenesis Holdings | 9.45M |
OpGen | 3.07M |
Soligenix | 839.36K |
SILO News
- 9 days ago - Silo Pharma Announces Positive Results for Intranasal PTSD Treatment - GlobeNewsWire
- 22 days ago - Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic - GlobeNewsWire
- 6 weeks ago - Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain - GlobeNewsWire
- 2 months ago - Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD - GlobeNewsWire
- 2 months ago - Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Positive Results in Alzheimer's Disease Study - GlobeNewsWire
- 4 months ago - Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD - GlobeNewsWire